NVO Stock Research, Signals & Filings

Drillr aggregates AI research, SEC filings, earnings signals, alt-data and financial tables for NVO. 3 published articles.

Latest Research

  1. LLY Stock Dips on Foundayo Approval — Is the GLP-1 Oral Drug a NVO Killer?

    Eli Lilly's shares fell despite Foundayo (orforglipron) FDA approval due to geopolitical tensions, but the oral GLP-1's no-restrictions profile positions it to challenge Novo's injectable dominance. LLY's stellar growth (45% revenue surge) contrasts Novo's slowdown (-5-13% 2026 guidance), making the dip a potential entry point. Watch initial uptake and competitive filings for share shifts.

    LLY

  2. LLY FDA Approval: Oral Obesity Pill Foundayo Threatens NVO's Wegovy as Revenue Surges 45%

    FDA approval of Lilly's oral obesity pill Foundayo (orforglipron) intensifies rivalry with Novo's Wegovy, with Lilly's superior growth and oral convenience poised to capture needle-averse patients. NVO's guidance cuts highlight vulnerabilities, favoring LLY overweight amid 45% revenue surge vs. NVO's 6%. Key: Q1 2026 uptake and Medicare dynamics.

    LLY

  3. FTC Insulin Crackdown: CVS Settles — What It Means for LLY, NVO, and WBA

    CVS Health's recent settlement with the FTC over insulin pricing marks a pivotal moment in the pharmaceutical landscape. This article analyzes the potential winners and losers among pharmacies and drugmakers as regulatory scrutiny intensifies, highlighting key players like Eli Lilly, Novo Nordisk, and Walgreens Boots Alliance.

    CVSWBALLY

Track NVO with Drillr

SEC filings, earnings calls, alt-data signals — all queryable through Drillr's AI terminal and MCP API.

Try drillr.ai for free